Experienced in Ewing Sarcoma

Dr. John M. Kaczmar

Oncology | Hematology Oncology
University Medical Associates Of The Medical University Of South Carol
171 Ashley Ave, 
Charleston, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Ewing Sarcoma
University Medical Associates Of The Medical University Of South Carol
171 Ashley Ave, 
Charleston, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Kaczmar is an Oncologist and a Hematologist Oncology provider in Charleston, South Carolina. Dr. Kaczmar is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Adenoid Cystic Carcinoma, and Glioma. Dr. Kaczmar is currently accepting new patients.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Musc Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UNIVERSITY MEDICAL ASSOCIATES OF THE MEDICAL UNIVERSITY OF SOUTH CAROL
171 Ashley Ave, Charleston, SC 29425

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection
A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Combination product
Study Drugs: Pembrolizumab, PDS0101
Study Phase: Phase 2
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Peposertib
Study Phase: Phase 1
A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma
A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Radiation, Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
Pilot Clinical Trial of Neoadjuvant Toll-like Receptor 7 Agonist (Imiquimod) Immunotherapy in Early-Stage Oral Squamous Cell Carcinoma
Pilot Clinical Trial of Neoadjuvant Toll-like Receptor 7 Agonist (Imiquimod) Immunotherapy in Early-Stage Oral Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Drug
Study Drug: Imiquimod
Study Phase: Early Phase 1
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug, Biological
Study Drugs: Ficlatuzumab, Cetuximab
Study Phase: Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: January 03, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

31 Total Publications

Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma.
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 31, 2025
Similar Doctors
Experienced in Ewing Sarcoma
Dr. Scott Lindhorst
Oncology | Neurology | Hematology Oncology
Experienced in Ewing Sarcoma
Dr. Scott Lindhorst
Oncology | Neurology | Hematology Oncology

University Medical Associates Of The Medical University Of South Carol

167 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Lindhorst is an Oncologist and a Neurologist in Charleston, South Carolina. Dr. Lindhorst is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Awake Craniotomy.

Experienced in Ewing Sarcoma
Dr. Andrew S. Kraft
Hematology Oncology
Experienced in Ewing Sarcoma
Dr. Andrew S. Kraft
Hematology Oncology
171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances

Andrew Kraft is a Hematologist Oncology provider in Charleston, South Carolina. Dr. Kraft is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Bone Tumor, Liposarcoma, and Fibrosarcoma.

Experienced in Ewing Sarcoma
Dr. David L. Milling
Hematology Oncology | Hematology | Oncology
Experienced in Ewing Sarcoma
Dr. David L. Milling
Hematology Oncology | Hematology | Oncology

Georgetown Memorial Hospital

606 Black River Rd, 
Georgetown, SC 
 (56.1 miles away)
843-527-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Milling is a Hematologist Oncology specialist and a Hematologist in Georgetown, South Carolina. Dr. Milling is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Non-Hodgkin Lymphoma, Pleuropulmonary Blastoma, Lung Cancer, and Paget Disease of the Breast. Dr. Milling is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kaczmar's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile